Novynta (Cytisinicline)

Cytisinicline is a selective partial agonist at the α4β2 nicotinic acetylcholine receptors in the brain. By providing modest receptor stimulation, it blunts the dopamine surge from nicotine while easing the dopamine deficit that drives cravings, thereby facilitating cessation.

The dosage of Novynta is individualized by the prescribing clinician based on the patient’s medical history, smoking pattern, and response to therapy. No fixed regimen is provided here; the prescriber determines the appropriate dose and titration schedule.

Limited clinical data exist for cytisinicline use during pregnancy or lactation. Because safety has not been established, the drug is generally not recommended for pregnant or nursing women unless the potential benefit outweighs the potential risk, as decided by a qualified health professional.

To request Novynta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

The most common alternative is varenicline, a full agonist at the same α4β2 receptors. Cytisinicline is a partial agonist, which may result in a milder side‑effect profile but similar efficacy in reducing cravings. Choice between the two depends on individual tolerance, comorbidities, and physician judgment.

Novynta should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink to maintain product stability.

Novynta is taken orally, usually as a tablet. The patient should swallow the tablet whole with a glass of water, preferably with or without food as directed by the prescriber. Do not crush, chew, or split the tablet unless instructed.

Serious risks include neuropsychiatric events such as depression, anxiety, or suicidal thoughts, severe allergic reactions (rash, swelling, breathing difficulty), and cardiovascular issues like chest pain or hypertension. Patients should seek immediate medical attention if any of these symptoms develop.

Novynta is contraindicated in individuals with known hypersensitivity to cytisinicline or any tablet excipients, patients with uncontrolled hypertension, and those currently using other nicotine replacement therapies without medical supervision. It should also be avoided in patients with severe hepatic impairment unless a specialist advises otherwise.